Europe Genomic Cancer Panel and Profiling Market to Grow at CAGR of 9.48% through 2029F

Integration of artificial intelligence and machine learning and government initiatives and funding is expected to drive the Europe Genomic Cancer Panel and Profiling Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Europe Genomic Cancer Panel and Profiling Market - By Country, Competition Forecast & Opportunities, 2029F”, the Europe Genomic Cancer Panel and Profiling Market stood at USD 2.48 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 9.48% through 2029.

The increasing adoption of personalized medicine represents a paradigm shift in healthcare, driven by advancements in genomic technology and a growing understanding of the molecular basis of disease. Personalized medicine aims to tailor medical treatment to the unique characteristics of each patient, including their genetic makeup, lifestyle factors, and environmental influences. Genomic cancer panels play a pivotal role in this approach by providing detailed genetic information that guides the selection of targeted therapies, improving treatment outcomes and minimizing adverse effects.

The shift towards personalized medicine is driven by the recognition that one-size-fits-all approaches to treatment may not be effective for all patients. By leveraging genomic information, healthcare providers can identify specific genetic mutations and molecular signatures associated with individual tumors, allowing for the selection of therapies that target these specific vulnerabilities. This precision-guided approach enhances the efficacy of treatment while minimizing unnecessary side effects, ultimately leading to better patient outcomes.

Personalized medicine has been shown to improve patient outcomes across a range of cancer types. Studies have demonstrated that patients who receive personalized treatment based on genomic profiling experience higher survival rates, longer progression-free survival, and improved quality of life compared to those receiving standard treatments. These positive outcomes underscore the clinical utility of genomic cancer profiling and highlight its potential to revolutionize cancer care.

Another emerging trend in the Europe Genomic Cancer Panel and Profiling Market is the rise of liquid biopsy-based genomic testing. Liquid biopsy techniques involve analyzing circulating tumor cells, cell-free DNA, or other biomarkers in bodily fluids such as blood, urine, or saliva. These non-invasive methods offer advantages over traditional tissue biopsies, including easier sample collection, real-time monitoring of disease progression, and the ability to capture tumor heterogeneity. Liquid biopsy-based genomic testing is gaining traction for its potential applications in early cancer detection, treatment monitoring, and identifying resistance mechanisms. With ongoing advancements in technology and increasing clinical validation, liquid biopsy-based genomic testing is poised to revolutionize cancer diagnosis and management, driving demand for comprehensive genomic profiling solutions in the European market. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Europe Genomic Cancer Panel and Profiling Market”

The Europe Genomic Cancer Panel and Profiling Market is segmented into application, end user, country distribution, and company.

Based on end user, hospitals emerged as the dominated segment. Hospitals serve as primary centers for cancer diagnosis, treatment, and patient care, making them integral to the delivery of oncology services. As such, hospitals have a vested interest in leveraging cutting-edge technologies, such as genomic profiling, to enhance their oncology capabilities and provide optimal care to cancer patients. The increasing prevalence of cancer across Europe has placed a growing burden on hospital systems, driving the need for more effective diagnostic and treatment modalities. Genomic cancer panels offer hospitals a valuable tool for precision oncology, enabling clinicians to identify specific genetic alterations in tumors and tailor treatment strategies accordingly. Hospitals often have access to multidisciplinary teams of healthcare professionals, including oncologists, pathologists, genetic counselors, and other specialists, who collaborate to deliver comprehensive cancer care. The integration of genomic profiling into hospital workflows allows for seamless coordination among these teams, facilitating informed clinical decision-making and personalized treatment planning for cancer patients. Hospitals have the infrastructure, resources, and expertise necessary to implement genomic testing protocols and interpret complex genomic data. With advancements in sequencing technologies and bioinformatics tools, hospitals can conduct genomic profiling in-house or through partnerships with specialized laboratories, ensuring timely and accurate results for patients.

Major companies operating in Europe Genomic Cancer Panel and Profiling Market are:

• Agilent Technologies Deutschland GmbH
• ARUP Laboratories
• Burning Rock Biotech Limited
• U.S. Caris MPI, Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Exact Sciences Europe, Ltd
• F. Hoffmann-La Roche Ltd

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The expansion of genomic profiling applications beyond cancer diagnosis and treatment is revolutionizing cancer management in Europe. Genomic testing is now being utilized for screening individuals with a predisposition to cancer, allowing for early identification of high-risk individuals and proactive interventions to prevent disease development. Genomic profiling plays a crucial role in the early detection of minimal residual disease, enabling clinicians to monitor disease recurrence and tailor treatment approaches accordingly. Genomic testing is instrumental in assessing treatment response and disease progression, guiding clinicians in optimizing therapeutic regimens and identifying potential resistance mechanisms. By providing insights into genetic predispositions and disease trajectories, comprehensive genomic testing solutions empower healthcare providers to deliver personalized treatment strategies tailored to each patient's unique genetic profile, ultimately improving treatment outcomes and patient survival rates.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Europe Genomic Cancer Panel and Profiling Market By Application (Clinical, Research), By End User (Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutes, Other End Users), By Country, Competition, Forecast and Opportunities, 2019-2029F”, has evaluated the future growth potential of Europe Genomic Cancer Panel and Profiling Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Europe Genomic Cancer Panel and Profiling Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com